All In Biotech

Drug Trial Radar · NCT05263453

HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation

A Single-arm, Multi-center Phase II Trial to Evaluate the Efficacy and Safety of the Combination of HL-085 and Vemurafenib in Advanced Melanoma Patients With BRAF V600E/K Mutation

Last checked: Nov 19, 2026Latest source record: May 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

104

Planned (sponsor's estimate)

Start

Sep 6, 2021

Primary completion

Sep 30, 2024

Study completion Dec 31, 2024

Sponsor

Lead sponsor
Shanghai Kechow Pharma, Inc.Industry
Sponsor type
Industry
First posted
Mar 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to Evaluate the Efficacy and Safety of the combination of HL-085 and Vemurafenib in Advanced Melanoma Patients with BRAF V600E/K Mutation. This study includes IIa and IIb phase. Phase IIa will determine the dose regiment for Phase IIb. Phase IIb part will evaluate the efficacy and safety with this combination regiment.

Conditions

  • Melanoma

Interventions

  • HL-085Drug

    HL-085 capsule 12mg administered orally twice daily in a 21-day treatment cycle

  • VemurafenibDrug

    Vemurafenib tablet 720mg administered orally twice daily in a 21-day treatment cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: up to 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.